Brian Warnecke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brian Warnecke has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Wehbe
Wayne State University School of Medicine Detroit Michigan USA
1 shared publicationAmmar Sukari
Karmanos Cancer Institute, Wayne State University, Detroit, MI
1 shared publicationAndrew Elliott
Caris Life Sciences, Irving, TX
1 shared publication- Annie Hung
Eli Lilly and Company, Indianapolis, IN
1 shared publication Asfar S. Azmi
Karmanos Cancer Institute, Wayne State University, Detroit, MI
1 shared publication- Balazs Halmos
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
1 shared publication
Latest Publications
- Open Access
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2) , 00022
Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes
PURPOSE: Regulator of chromosome condensation 1 ( RCC1 ) and RCC2 have been shown to play important roles in the regulation of cell cycle, DNA damage response, and nucleocytoplasmic transport. MATERIALS AND METHODS: DNA (592-gene or whole exome) and RNA (whole transcriptome) sequencing was performed at Caris Life Sciences (Phoenix, AZ). Samples were stratified by RCC1 expression quartile thresholds (Q1: low, Q4: high) for small cell lung cancer (SCLC; n = 876), non–small cell lung cancer (NSCLC; n = 21,603), gastric cancer (GC; n = 1,908), pancreatic cancer (PC; n = 5,071), and colorectal cancer (CRC; n = 14,892). Statistical significance was determined using chi-square and Wilcoxon rank-sum tests and adjusted for multiple comparisons (* P < .05). Corresponding analyses were run for RCC2 . RESULTS: Median RCC1 mRNA expression was highest in SCLC (14.3 transcript per million [TPM]), followed by GC (9.9), NSCLC (9.9), CRC (9.8), and PC (6.9). Similar to RCC1 , the median RCC2 expressions were highest in SCLC (36.2 TPM). Tumor mutational burden-high rates were positively associated with increasing RCC1 expression quartiles (Q1-4) in NSCLC (31%-41%), GC (7%-22%), and CRC (5%-17%) and with increasing RCC2 expression in NSCLC and CRC only. Higher expression with RCC1 and RCC2 was associated with worse overall survival in NSCLC (hazard ratio [HR] for RCC1 and RCC2 were 1.3 and 1.3, respectively), PC (HR for RCC1 and RCC2 were 1.5 and 1.12, respectively), and CRC (HR for RCC1 and RCC2 were 1.3 and 1.03, respectively). CONCLUSION: RCC1 and RCC2 expression is a negative prognostic marker in NSCLC, PC, and CRC. Further studies to investigate RCC1 and RCC2 function at the molecular level may provide opportunities for novel targeted drug development.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2) , 00022
Open AccessMultiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes
PURPOSE: Regulator of chromosome condensation 1 ( RCC1 ) and RCC2 have been shown to play important roles in the regulation of cell cycle, DNA damage response, and nucleocytoplasmic transport. MATERIALS AND METHODS: DNA (592-gene or whole exome) and RNA (whole transcriptome) sequencing was performed at Caris Life Sciences (Phoenix, AZ). Samples were stratified by RCC1 expression quartile thresholds (Q1: low, Q4: high) for small cell lung cancer (SCLC; n = 876), non–small cell lung cancer (NSCLC; n = 21,603), gastric cancer (GC; n = 1,908), pancreatic cancer (PC; n = 5,071), and colorectal cancer (CRC; n = 14,892). Statistical significance was determined using chi-square and Wilcoxon rank-sum tests and adjusted for multiple comparisons (* P < .05). Corresponding analyses were run for RCC2 . RESULTS: Median RCC1 mRNA expression was highest in SCLC (14.3 transcript per million [TPM]), followed by GC (9.9), NSCLC (9.9), CRC (9.8), and PC (6.9). Similar to RCC1 , the median RCC2 expressions were highest in SCLC (36.2 TPM). Tumor mutational burden-high rates were positively associated with increasing RCC1 expression quartiles (Q1-4) in NSCLC (31%-41%), GC (7%-22%), and CRC (5%-17%) and with increasing RCC2 expression in NSCLC and CRC only. Higher expression with RCC1 and RCC2 was associated with worse overall survival in NSCLC (hazard ratio [HR] for RCC1 and RCC2 were 1.3 and 1.3, respectively), PC (HR for RCC1 and RCC2 were 1.5 and 1.12, respectively), and CRC (HR for RCC1 and RCC2 were 1.3 and 1.03, respectively). CONCLUSION: RCC1 and RCC2 expression is a negative prognostic marker in NSCLC, PC, and CRC. Further studies to investigate RCC1 and RCC2 function at the molecular level may provide opportunities for novel targeted drug development.
- Open Access
- 16 January 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (1)
COVID‐19‐induced thrombotic microangiopathy: A great mimicker of thrombotic thrombocytopenic purpura ( TTP )
We present a unique case of a 68‐year‐old male who was diagnosed with COVID‐19. His hospital course was complicated by widespread thrombosis, renal failure, and thrombocytopenia. Thrombotic thrombocytopenic purpura was initially suspected, yet plasma exchange and steroids did not improve his disease. Ultimately, he was diagnosed with COVID‐19‐induced thrombotic microangiopathy.
- 16 January 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (1)
Open AccessCOVID‐19‐induced thrombotic microangiopathy: A great mimicker of thrombotic thrombocytopenic purpura ( TTP )
We present a unique case of a 68‐year‐old male who was diagnosed with COVID‐19. His hospital course was complicated by widespread thrombosis, renal failure, and thrombocytopenia. Thrombotic thrombocytopenic purpura was initially suspected, yet plasma exchange and steroids did not improve his disease. Ultimately, he was diagnosed with COVID‐19‐induced thrombotic microangiopathy.
- 20 May 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (15_suppl) , e17612
Outcomes of statin use in veterans with prostate cancer: A retrospective single-center experience.
E17612 Background: Prostate cancer is the most common cancer in men in the United States. Death in prostate cancer patients is often reported to be non-prostate cancer related, attributed to other medical conditions. As prostate cancer is associated with a prolonged survival, care of these patients includes optimizing other co-morbidities, such as cardiovascular disease. There are multiple reports and epidemiological studies of statins decreasing the risk, progression, and overall mortality of prostate cancer. Previously we had gathered data on 300 patients diagnosed with prostate cancer at the VA in San Antonio. The results indicated that using statins has a statistically significant positive effect at delaying death by prostate cancer, with a p-value of 0.018. We have updated our results with the addition of 105 patients. Methods: This is a retrospective observational study with chart review of 405 patients diagnosed with prostate cancer from 1995 to 2010, in a VA Hospital in San Antonio, Texas. Variables included age of diagnosis, statin use, type of statin (1st, 2nd, or 3rd generation), dose of statin (6 levels of dosage were identified), length of statin use, time followed in months (from time of diagnosis to either death or the end of the study period), death, and cause of death. The Cox proportional hazards regression model was used to estimate the hazard function, with age at diagnosis used as a covariate. Primary end point was death by prostate cancer (33 patients) and secondary end points- death by any cancer (71 patients), and death by all causes (205 patients). Results: The hazard ratio for use of statins at least 6 months was 0.56, with 95% confidence limits of 0.41 to 1.13, and a p-value of 0.118, indicating no statistically significant effect of statin usage and delay in death by prostate cancer. Secondary endpoint of death by all causes was significantly affected by statins, while death by any cancer showed no significant effect. The study was unable to conclude if the type of statin, dose of statin or the length of statin use had a significant effect in reaching the different end points. Conclusions: The addition of 105 more patients to this study has changed our previous statistically significant primary endpoint results.Concomitant statin use may not help prevent death from prostate cancer or death from any cancer, but may help prevent death from all causes. This updated primary endpoint data conflicts with multiple prior epidemiological studies and raises questions on the impact of statin usage on men with prostate cancer.
- 20 May 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (15_suppl) , e17612
Outcomes of statin use in veterans with prostate cancer: A retrospective single-center experience.
E17612 Background: Prostate cancer is the most common cancer in men in the United States. Death in prostate cancer patients is often reported to be non-prostate cancer related, attributed to other medical conditions. As prostate cancer is associated with a prolonged survival, care of these patients includes optimizing other co-morbidities, such as cardiovascular disease. There are multiple reports and epidemiological studies of statins decreasing the risk, progression, and overall mortality of prostate cancer. Previously we had gathered data on 300 patients diagnosed with prostate cancer at the VA in San Antonio. The results indicated that using statins has a statistically significant positive effect at delaying death by prostate cancer, with a p-value of 0.018. We have updated our results with the addition of 105 patients. Methods: This is a retrospective observational study with chart review of 405 patients diagnosed with prostate cancer from 1995 to 2010, in a VA Hospital in San Antonio, Texas. Variables included age of diagnosis, statin use, type of statin (1st, 2nd, or 3rd generation), dose of statin (6 levels of dosage were identified), length of statin use, time followed in months (from time of diagnosis to either death or the end of the study period), death, and cause of death. The Cox proportional hazards regression model was used to estimate the hazard function, with age at diagnosis used as a covariate. Primary end point was death by prostate cancer (33 patients) and secondary end points- death by any cancer (71 patients), and death by all causes (205 patients). Results: The hazard ratio for use of statins at least 6 months was 0.56, with 95% confidence limits of 0.41 to 1.13, and a p-value of 0.118, indicating no statistically significant effect of statin usage and delay in death by prostate cancer. Secondary endpoint of death by all causes was significantly affected by statins, while death by any cancer showed no significant effect. The study was unable to conclude if the type of statin, dose of statin or the length of statin use had a significant effect in reaching the different end points. Conclusions: The addition of 105 more patients to this study has changed our previous statistically significant primary endpoint results.Concomitant statin use may not help prevent death from prostate cancer or death from any cancer, but may help prevent death from all causes. This updated primary endpoint data conflicts with multiple prior epidemiological studies and raises questions on the impact of statin usage on men with prostate cancer.